Drug Interactions (7.1)]. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal syndrome in adults, may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. Drug Interactions (7.1, Homatropine methylbromide 1.5 MG / hydrocodone bitartrate 5 MG per 5 ML Syrup uses DESCRIPTION This product contains hydrocodone (dihydrocodeinone) bitartrate, a semisynthetic centrally-acting narcotic antitussive. Addiction can occur at recommended dosages and if the drug is misused or abused. Opioids may cause increases in serum amylase [ The information available does not identify any particular opioids as being more likely to be associated with adrenal insufficiency. Physostigmine may be used parenterally for the treatment of the signs and symptoms of homatropine toxicity. see 33; Glycerin, USP; Liquid Sugar; Methylparaben, NF; Propylene Glycol, USP; Propylparaben, NF and Sorbitol Solution, USP. Reevaluate patients with unresponsive cough in 5 days or sooner for possible underlying pathology, such as foreign body or lower respiratory tract disease [ Do not overfill. However, this effect is not consistent and may be offset by an increased rate of cervical dilation, which tends to shorten labor. (, Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg /1.5 mg per 5 mL is not recommended for use in pregnant women. Health care providers should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical dependence in all addicts. It is present in antitussives, under the trade name Hycodan, in combination with bitartrate hydrocodone (dihydrocodeinone), indicated as an oral tablet or solution for the symptomatic relief of cough. Do not abruptly discontinue Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL in a physically-dependent patient [, Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL contains hydrocodone, a Schedule II controlled substance. see The related chemical compound homatropine methylbromide (methylhomatropine) is a different medication. It is not known whether this drug is excreted in human milk. All patients treated with opioids require careful monitoring for signs of abuse and addiction, since use of opioid analgesic and antitussive products carries the risk of addiction even under appropriate medical use. The use of MAOIs or tricyclic antidepressants with hydrocodone, one of the active ingredients in Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL, may increase the effect of either the antidepressant or hydrocodone. Anticholinergic agents can also precipitate acute narrow angle glaucoma. DOSAGE AND ADMINISTRATION It is important that HYCODAN oral solution is measured with an accurate measuring device (see PATIENT INFORMATION ). Inform patients not to take Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL while using or within 14 days of stopping any drugs that inhibit monoamine oxidase. A household teaspoon is not an accurate measuring device and could lead to overdosage [ Warnings and Precautions (5.2), You may enter multiple email addresses separated by semicolons. see decrease in mental and physical performance. 33; Glycerin, USP; Liquid Sugar; Methylparaben, NF; Propylene Glycol, USP; Propylparaben, NF and Sorbitol Solution, USP. To reduce the risk of respiratory depression, proper dosing of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL is essential [, Children are particularly sensitive to the respiratory depressant effects of hydrocodone [, Use of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL in children also exposes them to the risks of addiction, abuse, and misuse [ Do not change your dose without talking to your healthcare provider. If the patient develops these signs or symptoms, raise the dose to the previous level and taper more slowly, either by increasing the interval between decreases, decreasing the amount of change in dose, or both. Hydrocodone Bitartrate And Homatropine Methylbromide Syrup | Direct Rx Motion SicknessThe initial dose of 25 to 50 mg of Meclizine HCI should be taken one hour prior to travel for protection against motion sickness. have a blockage (obstruction) in your bowel such as a paralytic ileus. Inform patients that Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL could cause adrenal insufficiency, a potentially life-threatening condition. Monitor patients closely, especially within the first 24-72 hours of initiating therapy or when used in patients at higher risk. see https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=63c966f5-21e5-47ae-96ba-c91b5477830f, https://dailymed.nlm.nih.gov/dailymed/rss.cfm. It is available as the hydrobromide salt. Concomitant use of opioids, including Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL, with benzodiazepines, or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. 2 retention (e.g., those with evidence of increased intracranial pressure or brain tumors), Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL may reduce respiratory drive, and the resultant CO "Doctor shopping" (visiting multiple prescribers to obtain additional prescriptions) is common among drug abusers and people suffering from untreated addiction. It is on the World Health Organization's List of Essential Medicines.[1]. The withdrawal signs include irritability and excessive crying, tremors, hyperactive reflexes, increased respiratory rate, increased stools, sneezing, yawning, vomiting and fever. Talk to your healthcare provider if this is a concern for you. see CYP3A4 mediated N-demethylation to norhydrocodone is the primary metabolic pathway of hydrocodone with a lower contribution from CYP2D6-mediated O-demethylation to hydromorphone. Events, (What Tell your healthcare provider if you take any of these medicines. ne of 2018. Life-threatening respiratory depression and death have occurred in children who received hydrocodone [ Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL is not recommended for use in pregnant women, including during or immediately prior to labor. We recommend using a newer internet browser, such as Google Chrome or Microsoft Edge, to optimize your browsing experience. There is a relationship between increasing hydrocodone plasma concentration and increasing frequency of dose-related opioid adverse reactions such as nausea, vomiting, CNS effects, and respiratory depression. ( ]. are allergic to hydrocodone, homatropine, or any of the ingredients in Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL. Advise patients how to recognize respiratory depression and to seek medical attention if breathing difficulties develop. Especially tell your healthcare provider if you: Ask your healthcare provider if you are not sure if you take one of these medicines. Use of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL in children also exposes them to the risks of addiction, abuse, and misuse [ Avoid the use of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL in patients taking benzodiazepines, other CNS depressants, or alcohol [ What is Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL? Furthermore, opioids produce adverse reactions that may obscure the clinical course of patients with head injuries. Instruct patients how to recognize symptoms of low blood pressure and how to reduce the risk of serious consequences should hypotension occur (e.g., sit or lie down, carefully rise from a sitting or lying position) [ Reserve Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL for use in adult patients for whom the benefits of cough suppression are expected to outweigh the risks, and in whom an adequate assessment of the etiology of the cough has been made. It is not known whether these effects on fertility are reversible [ Contact local state professional licensing board or state controlled substances authority for information on how to prevent and detect abuse or diversion of this product. ], in patients with chronic pulmonary disease or decreased respiratory reserve, and in patients with altered pharmacokinetics or altered clearance (e.g. this version. In excessive doses, hydrocodone, like other opium derivatives, will depress respiration. Patient Counseling Information (17)]. see Use of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL in children also exposes them to the risks of addiction, abuse, and misuse [ ]. (current). see Inform patients that accidental ingestion, especially by children, may result in respiratory depression or death [ You may accidently take too much. Use caution when considering the use of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL in patients 65 years of age or older. Avoid the use of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL in patients with circulatory shock.In patients with circulatory shock, Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL may cause vasodilation that can further reduce cardiac output and blood pressure. Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death. 2 basis with maternal oral doses of codeine at 30 mg/kg/day in rabbits and 600 mg/kg/day in mice). It is a peripherally acting anticholinergic medication that inhibits muscarinic acetylcholine receptors and thus the parasympathetic nervous system. The dosage of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL should not be increased if cough fails to respond; an unresponsive cough should be reevaluated for possible underlying pathology [ Warnings and Precautions (5.8), ]. Inform patients and caregivers that potentially fatal additive effects may occur if Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL is used with benzodiazepines or other CNS depressants, including alcohol. Inform female patients of reproductive potential that use of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated [ see Breathing problems (respiratory depression) that can lead to death and opioid withdrawal, Severe drowsiness, breathing problems (respiratory depression), coma, and death. This Medication Guide has been approved by the U.S. Food and Drug Administration. Monitor patients closely for respiratory depression, especially within the first 24-72 hours of initiating therapy [ 7.4)]. Dosage and Administration (2.1), 1), Important Limitations of Use ( Close No Recall More Info 2 basis, respectively). What is the most important information I should know about Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL? Department of Health and Human Services. Dispense in a tight, light-resistant container, as defined in the USP. InChI=1S/C16H21NO3/c1-17-12-7-8-13(17)10-14(9-12)20-16(19)15(18)11-5-3-2-4-6-11/h2-6,12-15,18H,7-10H2,1H3/t12-,13+,14+,15? When a patient who has been taking Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL regularly and may be physically dependent no longer requires therapy with Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL, taper the dose gradually, by 25% to 50% every 2 to 4 days, while monitoring carefully for signs and symptoms of withdrawal. Advise patients that use of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL is not recommended during pregnancy [ Dosage and Administration (2.3), 5), Common adverse reactions include: Sedation (somnolence, mental clouding, lethargy), impaired mental and physical performance, lightheadedness, dizziness, headache, dry mouth, nausea, vomiting, and constipation. Assess each patient's risk prior to prescribing Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL, prescribe Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL for the shortest duration that is consistent with individual patient treatment goals, monitor all patients regularly for the development of addition or abuse, and refill only after reevaluation of the need for continued treatment [, Serious, life-threatening, or fatal respiratory depression may occur with use of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL. Measure Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL oral solution with an accurate milliliter measuring device. Although the extent of protein binding of hydrocodone in human plasma has not been definitively determined, structural similarities to related opioid analgesics suggest that hydrocodone is not extensively protein bound. Call your doctor for medical advice about side effects. Rinse the measuring device with water after each use. Warnings and Precautions (5.5)]. Increased pressure in your head (intracranial). If concomitant use of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL with a CYP3A4 inhibitor or inducer is necessary, monitor patients for signs and symptoms that may reflect opioid toxicity and opioid withdrawal [ Marked mydriasis rather than miosis may be seen with hypoxia in overdose situations [ ]. The narcotic antagonist naloxone hydrochloride is a specific antidote for respiratory depression which may result from overdosage or unusual sensitivity to narcotics including hydrocodone. To reduce the risk of respiratory depression, proper dosing of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL is essential [ Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. see Primary attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and the institution of assisted or controlled ventilation. Prolonged use of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL during pregnancy can result in withdrawal in the neonate. see The hydrocodone in Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL may cause spasm of the sphincter of Oddi, resulting in an increase in biliary tract pressure. ( Dosing errors can result in accidental overdose and death. Methodological limitations of these observational studies include small sample size and lack of details regarding dose, duration and timing of exposure. View the latest press releases, feature stories, and company resources. Avoid the use of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL in patients taking a CYP3A4 inhibitor or inducer [ Hydrocodone can produce drug dependence of the morphine type and, therefore, has the potential for being abused. Drug Interactions (7.2, Hydrocodone Bitartrate / Homatropine Methylbromide 5 mg - 1.5 mg / 5 mL Syrup Unit Dose Cup 5 mL CII, Hydrocodone Bitartrate / Homatropine Methylbromide 5 mg - 1.5 mg Tablet Bottle 100 Tablets CII, Codeine Phosphate / Guaifenesin 10 mg - 100 mg / 5 mL Liquid Bottle 473 mL CV, Hydrocodone Bitartrate / Homatropine Methylbromide 5 mg - 1.5 mg / 5 mL Syrup Bottle 16 oz. After stopping a CYP3A4 inducer, as the effects of the inducer decline, the hydrocodone plasma concentration will increase [ Warnings and Precautions (5.15)]. What should I avoid while taking Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL? Opioids are sought by drug abusers and people with addiction disorders and are subject to criminal diversion. naloxone), depending on the patient's clinical status [, While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL, the risk is greatest during the initiation of therapy, when Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL is used concomitantly with other drugs that may cause respiratory depression [ For prescriptions where a measuring device is not provided, a pharmacist can provide an appropriate calibrated measuring device and can provide instructions for measuring the correct dose. Associates, Inc. 0121-4811-40. Do not use a household teaspoon to measure your medicine. Mutagenicity studies with hydrocodone have not been conducted. It is not known if these fertility problems will be reversible, even after you stop taking Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL. Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL is contraindicated for: Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL is also contraindicated in patients with:Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL is also contraindicated in patients with: Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL contains hydrocodone, a Schedule II controlled substance. Data). Warnings and Precautions (5.1)]. The concomitant use of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL and CYP3A4 inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g. An opioid antagonist, such as naloxone, must be available for reversal of opioid-induced respiratory depression in the neonate. Clinical Pharmacology (12.2)]. Consider these risks when prescribing or dispensing Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL. see Overdosage (10)]. elderly, cachectic, or debilitated patients) [ see Inactive ingredients in Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL oral solution: Caramel, NF; Cherry Flavor; D&C Red No. For clinically significant respiratory or circulatory depression secondary to hydrocodone overdose, administer an opioid antagonist. Prolonged use of opioids during pregnancy may cause neonatal opioid withdrawal syndrome [ Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL is a combination of hydrocodone, an opioid agonist; and homatropine, a muscarinic antagonist, indicated for the symptomatic relief of cough in patients 18 years of age and older. The effects of hydrocodone in therapeutic doses on the cardiovascular system are insignificant. Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL is contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus [ Use in Specific Populations (8.3)]. Hydrocodone exhibits a complex pattern of metabolism including O-demethylation, N-demethylation and 6-keto reduction to the corresponding 6--and 6--hydroxymetabolites. Children Dosage: Use accurate measuring device. DailyMed will deliver notification of updates and additions to Drug Label information currently shown on this site through its RSS feed. Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL is a federal controlled substance (C-II) because it contains hydrocodone that can be abused or lead to dependence. Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL is not recommended for use in pregnant women [ see Gastrointestinal: Abdominal pain, bowel obstruction, decreased appetite, diarrhea, difficulty swallowing, dry mouth, GERD, indigestion, pancreatitis, paralytic ileus, biliary tract spasm (spasm of the sphincter of Oddi). Adverse Reactions (6)]. Monitor patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed. ]. It occurs as a fine white crystal or crystalline powder, which is derived from the opium alkaloid, thebaine. Risks Specific to Abuse of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL. In opioid-tolerant patients, the situation may be altered by the development of tolerance to opioid-related adverse reactions. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. Keep Dmitry Sazonov medicines away from animals and children. Taking Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL with certain other medicines can cause side effects or affect how well Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL or the other medicines work. Following a 10 mg oral dose of hydrocodone administered to five adult male subjects, the mean peak concentration was 23.6 5.2 ng/mL. see Homatropine methylbromide ( INN; also known as methylhomatropine bromide) is a quaternary ammonium salt of methylhomatropine. Around 200 million people worldwide take one of our medicines every day. (, Accidental ingestion of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg /1.5 mg per 5 mL, especially by children, can result in a fatal overdose of hydrocodone. However, psychic dependence is unlikely to develop when hydrocodone bitartrate and homatropine methylbromide is used for a short time for the treatment of cough. Use in Specific Populations (8.1)]. ]. Endocrine/Metabolic: Cases of serotonin syndrome, a potentially life-threatening condition, have been reported during concomitant use of opioids with serotonergic drugs. (, Concomitant use with CYP3A4 inhibitors (or discontinuation of CYP3A4 inducers) can result in a fatal overdose of hydrocodone. Use in Specific Populations (8.1), Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL can cause serious side effects, including: Keep Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL in a safe place away from children. Citric Acid, USP or Sodium Citrate, USP may be added for pH adjustment. see Warnings and Precautions (5.4)]. There are no data on the presence of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL in human milk, the effects of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL on the breastfed infant, or the effects of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL on milk production; however, data are available with hydrocodone and homatropine. take pain medicines such as opioids (narcotics). Hydrocodone is a semisynthetic narcotic antitussive and analgesic with multiple actions qualitatively similar to those of codeine. Respiratory depression is the chief risk for elderly patients treated with opioids, including Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL. Set id: 95828fad-323e-4510-acbf-6d354b25b887, hydrocodone bitartrate and homatropine methylbromide syrup. Who should not take Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL? see by: Pharmaceutical Associates, Inc. For prescriptions where a measuring device is not provided, a pharmacist can provide an appropriate measuring device and can provide instructions for measuring the correct dose. Opioid analgesics and antitussives, including hydrocodone, one of the active ingredients in Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL, should not be used in patients with acute febrile illness associated with productive cough or in patients with chronic respiratory disease where interference with ability to clear the tracheobronchial tree of secretions would have a deleterious effect on the patient's respiratory function. This medication is generally used for short-term treatment. Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, and other opioids, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death. Dosage and Administration (2.3), see Other: Drug abuse, drug dependence, opioid withdrawal syndrome. Advise both patients and caregivers about the risks of respiratory depression and sedation if Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL is used with benzodiazepines, alcohol, or other CNS depressants [, Patients must not consume alcoholic beverages, or prescription or non-prescription products containing alcohol, while on Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL therapy.